[
  {
    "ts": null,
    "headline": "Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness",
    "summary": "Event context and recent stock performance Without a specific headline event driving today’s move, Charles River Laboratories International (CRL) is drawing attention after a one-month return of about a 28% decline and a year-to-date decline near 22%. See our latest analysis for Charles River Laboratories International. The recent 30 day share price return of a 28.08% decline, alongside a year to date share price return of a 21.94% decline, contrasts with a 1 year total shareholder return of...",
    "url": "https://finnhub.io/api/news?id=040795359eae472c45ccedcc8b95b772f7febba1b9a7a393869fa0ebf572fe94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771510332,
      "headline": "Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness",
      "id": 139149337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Event context and recent stock performance Without a specific headline event driving today’s move, Charles River Laboratories International (CRL) is drawing attention after a one-month return of about a 28% decline and a year-to-date decline near 22%. See our latest analysis for Charles River Laboratories International. The recent 30 day share price return of a 28.08% decline, alongside a year to date share price return of a 21.94% decline, contrasts with a 1 year total shareholder return of...",
      "url": "https://finnhub.io/api/news?id=040795359eae472c45ccedcc8b95b772f7febba1b9a7a393869fa0ebf572fe94"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Overweight on Charles River, Lowers Price Target to $200",
    "summary": "Barclays  analyst Luke Sergott   maintains Charles River (NYSE:CRL) with a Overweight and lowers the price target from $215 to $200.",
    "url": "https://finnhub.io/api/news?id=3d491af4342602d6fc04c0ddea3b7b9ae35d15a676533dab8734ef93aa2a6fb7",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771501943,
      "headline": "Barclays Maintains Overweight on Charles River, Lowers Price Target to $200",
      "id": 139158708,
      "image": "",
      "related": "CRL",
      "source": "Benzinga",
      "summary": "Barclays  analyst Luke Sergott   maintains Charles River (NYSE:CRL) with a Overweight and lowers the price target from $215 to $200.",
      "url": "https://finnhub.io/api/news?id=3d491af4342602d6fc04c0ddea3b7b9ae35d15a676533dab8734ef93aa2a6fb7"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Group Maintains Outperform on Charles River, Lowers Price Target to $200",
    "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $260 to $200.",
    "url": "https://finnhub.io/api/news?id=50cf8e4abece5e618d83984c484a355f74c4e77a8cb295749871fdc31cea5eea",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771496055,
      "headline": "Evercore ISI Group Maintains Outperform on Charles River, Lowers Price Target to $200",
      "id": 139147413,
      "image": "",
      "related": "CRL",
      "source": "Benzinga",
      "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $260 to $200.",
      "url": "https://finnhub.io/api/news?id=50cf8e4abece5e618d83984c484a355f74c4e77a8cb295749871fdc31cea5eea"
    }
  },
  {
    "ts": null,
    "headline": "CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers",
    "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of $2.39 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=5727f5dfb43c470e250b0e209145a057ccc59ac64ac1c590bc7707d3f20681ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771479235,
      "headline": "CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers",
      "id": 139149338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of $2.39 per share was 1.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=5727f5dfb43c470e250b0e209145a057ccc59ac64ac1c590bc7707d3f20681ee"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments",
    "summary": "Charles River Laboratories International reported fourth-quarter 2025 revenue of US$994.23 million with a net loss of US$276.56 million, alongside full-year 2025 revenue of US$4.02 billion and a net loss of US$144.34 million driven in part by sizeable goodwill and intangible asset impairments. At the same time, the company issued 2026 guidance calling for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30–US$6.80, while appointing veteran healthcare finance executive Glenn G...",
    "url": "https://finnhub.io/api/news?id=d32e603e33950db9b6cd7c9db772e243bbec96d877d0b1e2bf2305a1eedf953c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771463653,
      "headline": "The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments",
      "id": 139141075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River Laboratories International reported fourth-quarter 2025 revenue of US$994.23 million with a net loss of US$276.56 million, alongside full-year 2025 revenue of US$4.02 billion and a net loss of US$144.34 million driven in part by sizeable goodwill and intangible asset impairments. At the same time, the company issued 2026 guidance calling for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30–US$6.80, while appointing veteran healthcare finance executive Glenn G...",
      "url": "https://finnhub.io/api/news?id=d32e603e33950db9b6cd7c9db772e243bbec96d877d0b1e2bf2305a1eedf953c"
    }
  }
]